Open terminalDashboard

Last updated Nov 19, 8:08 AM ET · 1 update

J&J Files With FDA to Expand CAPLYTA to Bipolar Mania

Johnson & Johnson said it filed for FDA approval to add bipolar mania as a fifth use for its drug CAPLYTA, citing two Phase 3 studies.

More on this company

  1. Johnson & Johnson announced via PRNewsWire on Thursday morning that it has asked the U.S. Food and Drug Administration (FDA) to approve CAPLYTA for treating manic or mixed episodes tied to bipolar I disorder, which would be a fifth approved use for the drug.

What happened

Johnson & Johnson said in its release that it is seeking FDA approval to expand CAPLYTA's use into bipolar mania, which would mark a fifth potential indication for the drug. The company said two Phase 3 studies found that CAPLYTA cut manic symptoms more than a placebo did, with effects showing up by day three and holding through the third week. PRNewsWire reported that CAPLYTA already carries FDA clearance for depression linked to both bipolar I and bipolar II, used either on its own or alongside other treatments, making it notable among drugs approved for that use in adults.

How the stock has moved

JNJ traded at $270.40 in pre-market trading, before the regular session opens, down 0.84% from Wednesday's close of $272.70, a decline that has held steady since the news was first reported.

Johnson & Johnson (JNJ) since the news
MeasureValue
Price, pre-market trading$270.40
Since the close before the first report (Wednesday, November 18, 2026)-0.84%
Change from the close on Wednesday, November 18, 2026-0.84%
Market value at the close on Wednesday, November 18, 2026$656.47 billion

Source: Stock quote; the close before the first report from our saved closes · as of November 19, 2026 at 8:08 AM ET · Shows what the stock did after the news was first reported, not why.

Its suppliers and customers

Among suppliers named in Johnson & Johnson's filings, Microsoft was up 1.67%, Citigroup was up 1.28%, and Martin Marietta Materials was up 1.50%, all outside the regular session. Intra-Cellular Therapies and Halda Therapeutics, also listed as suppliers, and Intra-Cellular Therapies and Shockwave, listed as customers, showed no trading activity since their last close.

Suppliers and customers of Johnson & Johnson, and how they are trading
CompanyRoleStockSince last close
MicrosoftSupplierMSFT+1.67%
CitigroupSupplierC+1.28%
Martin Marietta MaterialsSupplierMLM+1.50%
Intra-Cellular TherapiesCustomerNot listed—
ShockwaveCustomerNot listed—
Intra-Cellular TherapiesSupplierNot listed—
Halda TherapeuticsSupplierNot listed—

Source: Relationships named in company filings (Earnings call transcript; SEC 10-K annual report); stock quotes · as of November 19, 2026 at 8:08 AM ET · A supplier or customer moving the same day is not evidence that one move caused the other.

Sources

  • — PRNewsWire

How this was made

Written from WiseView data and the sources credited above, and checked before it went up. It is updated as new reports come in, and every update is checked before it goes up. How this report is made

For information only, not investment advice.

More from the desk

Follow MSFT, MLM and C in the terminal.

Every panel, HootAI, the squawk and the pre-market board, on one membership.

Annual

$83/mo

Billed annually, $997 once a year.

Monthly

$127/mo

Billed monthly. Cancel any time.

14-day free trial · no card needed · nothing to cancel. Buying for a team? Seats on one invoice.